Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.23
Dollar change
+0.19
Percentage change
9.31
%
IndexRUT P/E- EPS (ttm)-0.94 Insider Own54.14% Shs Outstand253.96M Perf Week9.31%
Market Cap566.64M Forward P/E- EPS next Y-0.89 Insider Trans0.00% Shs Float116.53M Perf Month-21.48%
Income-234.63M PEG- EPS next Q-0.21 Inst Own27.92% Short Float8.90% Perf Quarter5.69%
Sales0.13M P/S4358.79 EPS this Y8.52% Inst Trans4.25% Short Ratio10.19 Perf Half Y41.14%
Book/sh2.58 P/B0.86 EPS next Y-5.12% ROA-27.81% Short Interest10.38M Perf Year0.45%
Cash/sh2.15 P/C1.04 EPS next 5Y-7.90% ROE-31.53% 52W Range1.32 - 3.97 Perf YTD14.95%
Dividend Est.- P/FCF- EPS past 5Y-15.28% ROI-32.96% 52W High-43.83% Beta-0.58
Dividend TTM- Quick Ratio16.07 Sales past 5Y428.28% Gross Margin-15074.62% 52W Low68.94% ATR (14)0.19
Dividend Ex-Date- Current Ratio16.07 EPS Y/Y TTM-25.84% Oper. Margin-192867.69% RSI (14)51.91 Volatility6.46% 9.75%
Employees224 Debt/Eq0.10 Sales Y/Y TTM-99.85% Profit Margin-180486.15% Recom1.67 Target Price6.67
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-522.32% Payout- Rel Volume1.16 Prev Close2.04
Sales Surprise306.25% EPS Surprise10.87% Sales Q/Q-99.97% EarningsFeb 29 BMO Avg Volume1.02M Price2.23
SMA20-2.98% SMA503.82% SMA2002.13% Trades Volume1,176,344 Change9.31%
Date Action Analyst Rating Change Price Target Change
Aug-28-23Downgrade JP Morgan Overweight → Neutral $15 → $5
Nov-14-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $7
Nov-11-22Downgrade Goldman Buy → Neutral $13 → $7
Oct-17-22Initiated H.C. Wainwright Buy $12
Jul-12-21Initiated Morgan Stanley Overweight $25
Jul-12-21Initiated JP Morgan Overweight $22
Jul-12-21Initiated Goldman Buy $30
Jul-12-21Initiated BofA Securities Buy $25
Mar-19-24 10:00AM
Mar-07-24 12:00PM
Mar-05-24 04:30PM
Feb-28-24 04:44PM
04:05PM
04:05PM Loading…
Feb-26-24 04:05PM
Jan-03-24 04:05PM
Nov-09-23 04:05PM
Nov-07-23 04:33PM
04:05PM
Oct-31-23 09:00AM
Sep-27-23 09:00AM
Sep-11-23 08:00AM
Aug-31-23 04:05PM
Aug-08-23 07:10PM
04:05PM Loading…
04:05PM
Jul-12-23 08:47AM
Jul-05-23 04:05PM
Jun-16-23 10:47AM
Jun-07-23 04:05PM
Jun-01-23 07:55AM
May-04-23 07:25PM
06:25PM
04:05PM
May-02-23 04:05PM
Apr-17-23 07:11AM
Mar-27-23 04:52AM
Mar-26-23 10:14AM
Feb-28-23 08:15PM
04:05PM
06:43AM Loading…
Feb-02-23 06:43AM
Jan-03-23 04:05PM
Dec-23-22 06:36AM
Dec-16-22 10:48AM
Dec-15-22 07:00AM
Dec-09-22 09:35AM
Dec-01-22 04:05PM
Nov-12-22 07:39AM
Nov-10-22 04:05PM
06:24AM
Nov-08-22 07:15PM
04:05PM
Nov-07-22 08:05AM
Nov-04-22 10:00AM
Nov-02-22 04:05PM
Oct-25-22 07:59AM
Oct-17-22 12:54PM
09:28AM
Oct-06-22 04:05PM
Oct-05-22 08:05AM
Sep-28-22 04:05PM
Sep-15-22 09:40AM
Sep-12-22 09:55AM
03:00AM
Aug-30-22 04:05PM
Aug-26-22 09:55AM
Aug-10-22 09:55AM
Aug-08-22 06:30AM
Aug-04-22 06:25PM
04:05PM
Jul-17-22 09:49AM
Jun-30-22 01:08PM
Jun-17-22 07:38AM
Jun-07-22 04:05PM
May-25-22 03:00PM
May-10-22 04:05PM
10:45AM
May-09-22 11:29AM
May-05-22 09:31AM
May-04-22 04:05PM
10:52AM
May-03-22 09:55AM
May-02-22 04:30PM
Mar-29-22 04:05PM
Mar-20-22 08:02AM
Mar-16-22 06:26AM
Mar-08-22 04:45PM
Feb-17-22 04:38PM
Jan-31-22 04:05PM
Jan-24-22 12:39PM
08:00AM
Jan-19-22 11:11AM
Jan-15-22 08:31AM
Jan-04-22 04:05PM
Dec-16-21 04:05PM
Dec-15-21 04:05PM
Dec-02-21 04:05PM
Nov-16-21 08:49AM
Nov-12-21 08:00AM
Sep-30-21 06:01PM
Sep-17-21 10:16AM
Sep-08-21 04:05PM
Aug-12-21 04:05PM
Jul-18-21 11:39AM
Jul-01-21 02:46PM
Jun-17-21 05:29PM
05:26PM
01:02PM
Jun-16-21 09:49PM
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klausner RichardDirectorAug 15 '23Sale2.2858,020132,286930,880Aug 17 04:23 PM